Drugs derived from phage display: from candidate identification to clinical practice

Area of Science:

• Biotechnology
• Drug Discovery
• Molecular Biology

Background:

• Phage display is a fundamental technology for identifying biological drugs, including peptides and antibodies.
• It allows for tailoring drug characteristics like potency and specificity.
• Unlike in vivo methods, it bypasses immunological tolerance, enabling broader antibody generation.

Purpose of the Study:

• To review the clinical development of drugs derived from phage display technology.
• To illustrate the utility of phage display through case studies.
• To provide insights into the challenges and successes in developing phage-derived drugs.

Main Methods:

• Review of case studies from candidate identification to clinical development.
• Analysis of the application of phage display in drug discovery.
• Examination of clinical trial data and outcomes for phage-derived therapeutics.

Main Results:

• Phage display has successfully yielded numerous drug candidates, with over 20 in late-stage trials or approved.
• The technology enables precise control over drug properties such as specificity and potency.
• Clinical development pathways for phage-derived drugs present unique challenges and opportunities.

Conclusions:

• Phage display is a powerful and versatile tool for discovering and developing novel biological drugs.
• Further research and development are needed to optimize the clinical translation of phage display-derived therapeutics.
• Case studies demonstrate the significant potential and practical application of phage display in modern medicine.